S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
NYSE:EHAB

Enhabit (EHAB) Stock Price, News & Analysis

$11.57
+0.23 (+2.03%)
(As of 03/27/2024 ET)
Today's Range
$11.35
$11.68
50-Day Range
$7.81
$11.57
52-Week Range
$7.12
$14.59
Volume
636,589 shs
Average Volume
933,307 shs
Market Capitalization
$580.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.08

Enhabit MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.86 Rating Score
Upside/​Downside
4.4% Upside
$12.08 Price Target
Short Interest
Healthy
9.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.17mentions of Enhabit in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
25.00%
From $0.24 to $0.30 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.76 out of 5 stars

Medical Sector

855th out of 939 stocks

Home Health Care Services Industry

7th out of 8 stocks

EHAB stock logo

About Enhabit Stock (NYSE:EHAB)

Enhabit, Inc. is a leading healthcare provider that offers Medicare-certified skilled home health and hospice services in the United States. The company operates in two segments: Home Health and Hospice, providing services to adult patients needing care, including skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. Enhabit's hospice services include in-home services to terminally ill patients and their families to address patients' physical needs, including pain control and symptom management, and emotional and spiritual support.

Enhabit operates home health agencies in approximately 34 states, with a concentration in the southern half of the United States. As of March 31, 2022, Enhabit operates in 252 home health agencies and 99 hospice agencies across 34 states. Enhabit provides practices to treat chronic diseases and conditions, including diabetes, arthritis, hypertension,  Alzheimer's disease, spinal stenosis, low vision,  Parkinson's disease, complex wound care, osteoporosis, and chronic pain, along with disease-specific plans for patients with diabetes, post-orthopedic surgery or injury, congestive heart failure,  and respiratory diseases.

Enhabit started as HealthSouth, founded in 1984 by Beam Scrushy and Richard Scrushy. In the early 2000s, the company restructured and rebranded into Encompass Health after being caught up in an accounting scandal. In Q2 of 2022, Enhabit, the healthcare and hospice division, became an independent public company, having completed its spinoff from Encompass Health Corporation. 

Barb Jacobsmeyer was named President and CEO of Enhabit Home Health & Hospice in June 2021. Jacobsmeyer came to Enhabit from Encompass Health, where she served as the company's executive vice president of operations. 

In Q3 of 2022, Enhabit, Inc. announced the acquisition of Caring Hearts Hospice, a locally-owned hospice agency in Texas. The acquisition adds four hospice locations in Texas to Enhabit's existing presence in the state. Ehnabit continues to expand, setting aside approximately one hundred million dollars to fund future mergers and acquisitions. 

Enhabit, Inc. is committed to providing high-quality care and service to patients and their families, and its success is a testament to its dedicated team of healthcare professionals. Enhabit is well-positioned to meet the growing demand for healthcare services in the United States as a leading home health and hospice service provider. With its focus on patient care and commitment to excellence, Enhabit is poised to continue to grow and succeed in the years ahead.

Enhabit's commitment to quality care has not gone unnoticed, as they have received numerous awards and recognitions for their services. In 2021, they were named a HomeCare Elite Top Agency for the 15th year. This recognition is given to the top-performing home health agencies in the United States. They have also received a 5-star rating from the Centers for Medicare & Medicaid Services (CMS) for their home health services, indicating their high quality and patient satisfaction.

Enhabit's success can be attributed to its skilled and compassionate staff and dedication to providing comprehensive and individualized patient care. Enhabit also recognizes the importance of emotional and spiritual support for their patients and their families, particularly in hospice care. Their hospice services include pain and symptom management, spiritual counseling, palliative and dietary counseling, social worker visits, and bereavement counseling services to meet terminally ill patients and their families' individual physical, spiritual, emotional, and psychosocial needs.

EHAB Stock Price History

EHAB Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
my top trade on these 9 tickers
This indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.
Breaking Down Enhabit: 3 Analysts Share Their Views
Recap: Enhabit Q4 Earnings
Enhabit, Inc. (NYSE:EHAB) Q3 2023 Earnings Call Transcript
See More Headlines
Receive EHAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enhabit and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Home health care services
Sub-Industry
N/A
Fax
N/A
Employees
10,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.08
High Stock Price Target
$15.00
Low Stock Price Target
$9.50
Potential Upside/Downside
+4.4%
Consensus Rating
Reduce
Rating Score (0-4)
1.86
Research Coverage
7 Analysts

Profitability

Net Income
$-80,500,000.00
Pretax Margin
-8.64%

Debt

Sales & Book Value

Annual Sales
$1.05 billion
Cash Flow
$2.70 per share
Book Value
$13.90 per share

Miscellaneous

Free Float
49,203,000
Market Cap
$580.35 million
Optionable
Optionable
Beta
1.86
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Ms. Barbara Ann Jacobsmeyer B.S. (Age 57)
    M.A., P.T., President, CEO & Director
    Comp: $1.26M
  • Ms. Crissy Buchanan Carlisle (Age 51)
    Executive VP & CFO
    Comp: $611.66k
  • Ms. Tanya R. Marion (Age 49)
    Chief Human Resources Officer
    Comp: $445.86k
  • Ms. Julie Diane Jolley B.S.N. (Age 51)
    R.N., Executive Vice President of Home Health & Hospice Operations
    Comp: $642.65k
  • Ms. Jeanne Kalvaitis B.S.N. (Age 66)
    R.N., Executive Vice President of Hospice Operations
    Comp: $288.38k
  • Mark Brewer
    Chief Investor Relations Officer
  • Mr. Dylan C. Black (Age 54)
    General Counsel & Secretary
  • Mr. Ronald L. Langham Jr. (Age 46)
    M.B.A., P.T., Executive Vice President of Clinical Excellence & Strategy

EHAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Enhabit stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enhabit in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" EHAB shares.
View EHAB analyst ratings
or view top-rated stocks.

What is Enhabit's stock price target for 2024?

7 Wall Street research analysts have issued 12 month target prices for Enhabit's shares. Their EHAB share price targets range from $9.50 to $15.00. On average, they expect the company's share price to reach $12.08 in the next twelve months. This suggests a possible upside of 4.4% from the stock's current price.
View analysts price targets for EHAB
or view top-rated stocks among Wall Street analysts.

How have EHAB shares performed in 2024?

Enhabit's stock was trading at $10.35 on January 1st, 2024. Since then, EHAB shares have increased by 11.8% and is now trading at $11.57.
View the best growth stocks for 2024 here
.

Are investors shorting Enhabit?

Enhabit saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 4,230,000 shares, a decrease of 17.7% from the February 29th total of 5,140,000 shares. Based on an average daily trading volume, of 612,600 shares, the short-interest ratio is currently 6.9 days. Currently, 9.6% of the company's shares are short sold.
View Enhabit's Short Interest
.

When is Enhabit's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EHAB earnings forecast
.

How were Enhabit's earnings last quarter?

Enhabit, Inc. (NYSE:EHAB) announced its earnings results on Wednesday, March, 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.01. The firm earned $260.60 million during the quarter, compared to analysts' expectations of $260.30 million. Enhabit had a positive trailing twelve-month return on equity of 1.55% and a negative net margin of 7.69%. During the same quarter last year, the business posted $0.32 earnings per share.

What guidance has Enhabit issued on next quarter's earnings?

Enhabit issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of 0.120-0.430 for the period, compared to the consensus EPS estimate of 0.220. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Who are Enhabit's major shareholders?

Enhabit's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.38%), Vanguard Group Inc. (11.38%), Van Lanschot Kempen Investment Management N.V. (4.40%), Paradice Investment Management LLC (4.00%), Dimensional Fund Advisors LP (3.72%) and UBS Group AG (3.32%). Insiders that own company stock include Barbara Ann Jacobsmeyer, Charles M Elson, Erin Hoeflinger, Gregory S Rush, Jeffrey Bolton, John E D D S Maupin Jr, L Edward Shaw Jr, Leo I Higdon Jr, Ronald Leroy Langham Jr and Tanya Renee Marion.
View institutional ownership trends
.

How do I buy shares of Enhabit?

Shares of EHAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:EHAB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners